Effects of intraoperative glucose administration on circulating metabolites and nitrogen balance during prolonged surgery

Chambrier, C.; Aouifi, A.; Bon, C; Saudin, F.; Paturel, Brigitte; Boulétreau, P

doi:10.1016/s0952-8180(99)00114-2

Cited by 20 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that with general anesthesia, there are changes in circulating substrates and hormones. [29][30][31] This may account for the elevated fatty acids in the present study, as has been noted previously. 29 The prolonged period of fasting (16-18 h) before surgery was likely also a contributing factor.…”

supporting

confidence: 82%

“…[29][30][31] This may account for the elevated fatty acids in the present study, as has been noted previously. 29 The prolonged period of fasting (16-18 h) before surgery was likely also a contributing factor. In the present study, glucose concentrations appeared to be somewhat increased in lean and overweight subjects, as the glucose concentrations were similar to those observed during general anesthesia in other studies.…”

supporting

confidence: 82%

See 1 more Smart Citation

The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes

et al. 2006

View full text Add to dashboard Cite

Background: Long-chain fatty acids (LCFAs) cross the plasma membrane via a protein-mediated mechanism involving one or more LCFA-binding proteins. Among these, FAT/CD36 has been identified as key LCFA transporter in the heart and skeletal muscle, where it is regulated acutely and chronically by insulin. In skeletal muscle, FAT/CD36 expression and/or subcellular distribution is altered in obesity and type 2 diabetes. There is limited information as to whether the expression of this protein is also altered in subcutaneous and/or visceral adipose tissue depots in human obesity or type 2 diabetes. Objectives: To compare (a) the expression of FAT/CD36 in subcutaneous and visceral adipose tissue depots in lean, overweight, and obese individuals and in type 2 diabetics, (b) to determine whether the protein expression of FAT/CD36 in these depots is associated with the severity of insulin resistance (type 2 diabetes4obese4overweight/lean) and (c) whether FAT/CD36 protein expression in these adipose tissue depots is associated with alterations in circulating substrates and hormones. Subjects: Subjects who were undergoing abdominal surgery and who were lean (n ¼ 10; three men, seven women), overweight (n ¼ 10; three men, seven women) or obese (n ¼ 7; one man, six women), or who had been diagnosed with type 2 diabetes (n ¼ 5; one man, four women) participated in this study. Measurements: Subcutaneous and visceral adipose tissue samples, as well as blood samples, were obtained from the subjects while under general anesthesia. Adipose tissue samples were analyzed for FAT/CD36 using Western blotting. Serum samples were analyzed for glucose, insulin, FFA and leptin. BMI was also calculated. Results: Subcutaneous adipose tissue FAT/CD36 expression was upregulated by þ 58, þ 76 and þ 150% in overweight, obese and type 2 diabetics, respectively. Relative to subcutaneous adipose tissue, visceral adipose tissue FAT/CD36 expression was upregulated in lean ( þ 52%) and overweight subjects ( þ 30%). In contrast, in obese subjects and type 2 diabetics, no difference in FAT/CD36 protein expression was observed between their subcutaneous and visceral adipose tissue depots (P40.05). The subcutaneous adipose tissue FAT/CD36 expression (R ¼ 0.85) and the visceral adipose tissue FAT/CD36 expression (R ¼ 0.77) were associated with alteration in BMI and circulating glucose and insulin. Conclusions: Subcutaneous adipose tissue FAT/CD36 expression is upregulated in obesity and type 2 diabetes. As FAT/CD36 expression is not different in lean, overweight and obese subjects, and was only increased in type 2 diabetics, it appears that visceral adipose tissue FAT/CD36 may respond in a less dynamic manner to metabolic disturbances than subcutaneous adipose tissue FAT/CD36.

show abstract

supporting

confidence: 82%

supporting

confidence: 82%

The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Even in young patients, therefore, more than one-third of glucose production depends on gluconeogenesis after 22 hours of fasting [19]. However, intraoperative glucose administration has not been performed routinely because high dose of glucose infusion might cause hyperglycemia [20][21][22][23][24] When the benefit of intraoperative glucose administration is assumed, lower amounts are now recommended [25]. However, aggressive glycemic control increased the incidence of hypoglycemic events and did not result in any significant improvement in clinical outcomes that can be achieved with moderate control [26].…”

Section: Discussionmentioning

confidence: 99%

Effect of Glucose Administration on the Metabolism during Surgery

Kitamura¹,

Hirokawa

Sako³

et al. 2016

J Diabetes Metab

View full text Add to dashboard Cite

show abstract

“…Some previous studies have shown that the administration of glucose during surgery can inhibit starvation-induced catabolism [1][2][3][4][5][6][7] and attenuate post-operative insulin resistance [8]. Furthermore, the degree of postoperative insulin resistance was found to be an independent factor associated with the length of the postoperative hospital stay [9].…”

Section: Introductionmentioning

confidence: 99%

Administration of low dose of glucose suppresses catabolism under general anaesthesia maintained with remifentanil

Yoshimura¹,

Tomita²,

Kusama³

et al. 2017

J Anesthesiol Clin Sci

View full text Add to dashboard Cite

Background: The aim of this prospective randomized controlled study was to examine the optimal rate of glucose administration for preventing catabolism under general anaesthesia maintained with remifentanil. Methods: Forty-five consecutive patients who were scheduled to undergo elective head and neck surgery were enrolled. The patients were divided into three groups and were treated with a glucose-free solution (Group G0) or a glucose solution at a rate of 0.07 g/kg/h (Group G1) or 0.14 g/kg/h (Group G2). The patients' plasma glucose, the plasma levels of ketone bodies, free fatty acids (FFA), 3-methylhistidine (3-MH), creatinine (Cr), Branched-Chain Amino Acid (BCAA), and stress hormones were measured every two hours until 6h (T6). Results:The plasma glucose levels of Group G2 were significantly higher than those of the other groups at T2, T4, and T6 (P<0.01); however, the plasma glucose levels of the three groups did not differ at POD1. Group G0 exhibited significantly higher plasma ketone body and BCAA levels (at T2, T4, and T6) and FFA levels (at T4 and T6). No significant inter-group differences in the plasma levels of 3-MH/Cr or stress hormones were observed. Conclusions: Intraoperative glucose administration at a rate of 0.07 g/kg/h under general anaesthesia inhibited catabolism without the risk of hyperglycaemia.

show abstract

Effects of intraoperative glucose administration on circulating metabolites and nitrogen balance during prolonged surgery

Cited by 20 publications

References 23 publications

The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes

The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes

Effect of Glucose Administration on the Metabolism during Surgery

Administration of low dose of glucose suppresses catabolism under general anaesthesia maintained with remifentanil

Contact Info

Product

Resources

About